Last reviewed · How we verify
NCT03499834: IVY03
A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy
Phase 2 trial testing Immune Killer Cells (IKC) in Non-small Cell Lung Cancer (NSCLC) Stage IV in 26 participants. Completed in 16 February 2020.
16 February 2020
Quick facts
| Lead sponsor | Ivy Life Sciences, Co., Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 26 |
| Start date | 5 December 2017 |
| Primary completion | 16 February 2020 |
| Estimated completion | 16 February 2020 |
| Sites | 2 locations across Taiwan |
Drugs / interventions tested
- Immune Killer Cells (IKC) — full drug profile →
Conditions studied
- Non-small Cell Lung Cancer (NSCLC) Stage IV — all drugs for Non-small Cell Lung Cancer (NSCLC) Stage IV →
Sponsor
Ivy Life Sciences, Co., Ltd — full company profile →
Who can join
20 and older, any sex, with Non-small Cell Lung Cancer (NSCLC) Stage IV. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, whole blood is drawn from the patient to be used to grow Immune Killer Cells (IKC). After proliferation, the IKC will be infused back into the patient to treat the cancer for a total of 24 weekly treatments. Possible adverse reaction can include slight fever and headache.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
Sanchez CE, Dowlati EP, Geiger AE, Chaudhry K, et al · · 2021 · cited 21× · PMID 33007496 · DOI 10.1016/j.bbmt.2020.09.030 -
Immune killer cells treatment for previously treated stage IV NSCLC patients.
Tseng YH, Ho CL, Chian CF, Chiang CL, et al · · 2024 · cited 1× · PMID 39169058 · DOI 10.1038/s41598-024-69587-x
Verify or expand the search:
- PubMed search for NCT03499834
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Immune Killer Cells (IKC)
Trials testing the same drug.
- NCT03515252 — Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer · Phase 1 · completed
Other Ivy Life Sciences, Co., Ltd trials
Trials by the same sponsor.
- NCT03515252 — Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03499834 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ivy Life Sciences, Co., Ltd
- Last refreshed: 16 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03499834.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing